| Literature DB >> 26247582 |
Xiaolong Luo1, Mingyu Li1, Chengqing Wu1, Qiang Xu1, Guang Chen1, Bruce E Dornseif1, Markus F Renschler1, Gary Koch2.
Abstract
Clinical trials that explore long-term endpoints may confound the analysis when post-study therapy effects are considered. This article introduces a procedure to mediate the effects of confounding and allow inferences of first-line experimental treatments in the presence of post-study therapy. The procedure is evaluated by intensive simulation analyses and applied to an analysis of a clinical cancer trial.Entities:
Keywords: Cancer trial; crossover; survival analysis
Mesh:
Year: 2015 PMID: 26247582 DOI: 10.1080/10543406.2015.1074916
Source DB: PubMed Journal: J Biopharm Stat ISSN: 1054-3406 Impact factor: 1.051